

CASE REPORT

Open Access

A deletion of *FGFR2* creating a chimeric IIIb/IIIc exon in a child with Apert syndrome

Aimee L Fenwick¹, Sarah C Bowdin², Regan EM Klatt² and Andrew OM Wilkie^{1*}

Abstract

Background: Signalling by fibroblast growth factor receptor type 2 (FGFR2) normally involves a tissue-specific alternative splice choice between two exons (IIIb and IIIc), which generates two receptor isoforms (FGFR2b and FGFR2c respectively) with differing repertoires of FGF-binding specificity. Here we describe a unique chimeric IIIb/c exon in a patient with Apert syndrome, generated by a non-allelic homologous recombination event.

Case Presentation: We present a child with Apert syndrome in whom routine genetic testing had excluded the *FGFR2* missense mutations commonly associated with this disorder. The patient was found to harbour a heterozygous 1372 bp deletion between *FGFR2* exons IIIb and IIIc, apparently originating from recombination between 13 bp of identical DNA sequence present in both exons. The rearrangement was not present in the unaffected parents.

Conclusions: Based on the known pathogenesis of Apert syndrome, the chimeric FGFR2 protein is predicted to act in a dominant gain-of-function manner. This is likely to result from its expression in mesenchymal tissues, where retention of most of the residues essential for FGFR2b binding activity would result in autocrine activation. This report adds to the repertoire of rare cases of Apert syndrome for which a pathogenesis based on atypical *FGFR2* rearrangements can be demonstrated.

Background


Apert syndrome (AS) is a severe malformation disorder with a birth prevalence of ~1 in 65,000, characterised by craniosynostosis (premature fusion of the cranial sutures) and bony or cutaneous syndactyly of the hands and feet [1]. Over 98% of cases are caused by one of two heterozygous mutations in exon IIIa of the fibroblast growth factor receptor 2 gene (*FGFR2*), encoding the amino acid substitutions Ser252Trp or Pro253Arg (Figure 1A; [2]). Many other pathogenic missense mutations of *FGFR2* have been described in patients with craniosynostosis (typically with diagnoses of Crouzon, Pfeiffer or Beare-Stevenson syndromes) but these are associated with less severe abnormalities of the limbs than are present in Apert syndrome [3]. *FGFR2* is one of four transmembrane FGFRs that mediate signalling downstream of fibroblast growth factor ligands (FGFs) and plays an important role in skeletal development and disease [4].

The mechanism underlying the exquisite genotype-phenotype correlation of Apert syndrome mutations (Figure 1A) needs to be understood in terms of the biology of FGF/receptor signalling and the structural pathophysiology of *FGFR2* mutations [5,6]. The *FGFR2* protein comprises three extracellular immunoglobulin-like domains (IgI, IgII, IgIII), a transmembrane (TM) domain and a cytoplasmic tyrosine kinase (TK) domain. Signalling occurs by trans-phosphorylation of the TK domains following dimerisation of receptor molecules mediated by binding extracellular FGF in a 2:2 complex [7]. Specificity of FGF binding is determined by the IgII and IgIII domains, and further elaborated by the mutually exclusive alternative splicing of exons IIIb and IIIc (Figure 1A) resulting in isoforms FGFR2b and FGFR2c respectively, which differ in the sequence of the second half of the IgIII domain. FGFR2b is expressed in ectoderm and interacts with specific FGFs (FGF3, FGF7, FGF10, FGF22) in the underlying mesenchyme while FGFR2c is restricted to mesenchyme and interacts with a wider repertoire of FGFs expressed in the ectoderm [8]. The narrow

* Correspondence: awilkie@hammer.imm.ox.ac.uk

¹Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK

Full list of author information is available at the end of the article



binding specificity of the *FGFR2b* isoform is largely determined by four key residues encoded near the beginning of the IIIb exon that provide specific contacts for FGF10 and related ligands [9]. The two common AS mutations (Ser252Trp and Pro253Arg)

introduce additional contacts with multiple FGFs. This results both in enhanced *FGFR2c* signalling mediated by physiological FGFs, and in illegitimate binding by mesenchymally expressed FGFs creating an autocrine loop [10-13]; reviewed by [5,14].

In addition to the point mutations in exon IIIa, there have been three *Alu* insertions and one deletion reported as causing AS [15,16]. Although in all cases the rearrangements affect exon IIIc rather than exon IIIa, this can nevertheless be understood in terms of a shared pathophysiological mechanism with the common AS mutations. It was shown experimentally that one of these rearrangements drove illegitimate expression of the *FGFR2b* splice form in fibroblasts, a mesenchymal derivative [16]. Hence the common factor linking exon IIIa missense mutations and exon IIIc rearrangements, both causing AS, appears to be the autocrine activation of signalling by FGF10 and/or related ligands in the mesenchyme [6,14-18].


Here, we report a patient with AS caused by a variant of this latter rearrangement mechanism, in whom a 1.4 kb deletion caused by non-allelic homologous recombination between exons IIIb and IIIc has given rise to a chimeric IIIb/IIIc exon in which the reading frame is maintained.

Case Presentation

The affected boy was the first child of healthy, non-consanguineous parents aged 24 years (mother) and 35 years (father) at the time of birth. He was born at term weighing 3.26 kg and noted to have a dysmorphic facial appearance with turribrachycephaly, open metopic suture, shallow orbits, a deviated nasal septum and high arched, non-cleft palate. Bilateral dacryocystoceles were present. In addition he had broad radially deviated thumbs, skin syndactyly of digits 2-4 in the hands and feet, and broad medially deviated great toes (Figure 2). Three-dimensional computed tomography of the skull demonstrated bicoronal synostosis; magnetic resonance imaging of the brain showed normal intracranial structures. Cervical spine radiographs were normal, but C1 and C2 were not well visualised. Developmental progress was normal at the age of 4 years and 11 months.

A clinical diagnosis of Apert syndrome was proposed and blood obtained for genetic testing. However, two different diagnostic labs were unable to identify any pathogenic variants after DNA sequence analysis of the IIIa and IIIc exons of *FGFR2*. Further DNA sequence analysis of additional exons of *FGFR2*, and other genes in which mutations have been identified in craniosynostosis syndromes (*FGFR1*, *FGFR3* and *TWIST1*) was also negative.

We designed a long-range PCR assay to further investigate the region around exon IIIc of *FGFR2*, looking for evidence of *Alu* insertions or other rearrangements. Amplification of a 2.5 kb region including exons IIIb and IIIc (forward primer 984 bp upstream of exon IIIb, 5'-GAATTTTCAGAAGGGAAGTATGGAGTAG-3', reverse primer 32 bp downstream of exon IIIc, 5'-ATAGCAGTCAACCAAGAAAAGGG-3') revealed an



apparent deletion in the patient sample of ~1.4 kb compared to the control (Figure 1B). DNA sequencing of this product confirmed the presence of a 1372 bp deletion with the breakpoints occurring in a 13 bp region of perfect homology shared by the IIIb and IIIc exons (Figure 1C). This deletion results in a chimeric IIIb/IIIc exon that retains the open-reading frame and comprises the first 63 bp of exon IIIb, the 13 bp region of homology, and the final 63 bp of exon IIIc. The deletion was not present in either parental sample indicating that it had arisen *de novo* in the child. Permission was not given to determine the parental origin of the deletion.

Discussion

The deletion identified in this patient is likely to have arisen by non-allelic homologous recombination between

the 13 bp regions of identity shared by the *FGFR2* IIIb and IIIc exons, and is expected to have two consequences. First, loss of competition between the alternative exons IIIb and IIIc may result in either constitutive splicing, or skipping, of the chimeric exon (however skipping would result in an out-of-frame translation product). Second, the chimeric exon will retain some particular IIIb or IIIc-like structural features, but lose others.

The selection of a particular exon (IIIb or IIIc) for *FGFR2* splicing is mediated by *cis* elements either in the adjacent intron (intronic splicing enhancer/silencer: ISE/ISS) or within the exon itself (exonic splicing silencer: ESS) that bind splicing regulatory proteins to either promote or inhibit tissue-specific splicing. To date, several of these elements have been identified in the intron separating *FGFR2* exons IIIb and IIIc, as well as one upstream of exon IIIb, one downstream of exon IIIc, and three within the exons (Figure 1A; [19]). Recently it has been shown that in the absence of tissue-specific regulators, *FGFR2c* is the default spliceform due to the stronger 3' splice site of exon IIIc and the presence of ISS and ESS elements around exon IIIb [20]. In epithelial cells, epithelial splicing regulatory proteins (ESRPs) bind to the ISE/ISS-3 element, suppressing use of the downstream exon IIIc 3' splice site and activating splicing of exon IIIb [20,21]. The deletion described here removes the entire intron between exons IIIb and IIIc, and therefore all known regulatory elements within this intron, as well as an ESS from each exon. It is difficult to predict exactly how the chimeric exon would be processed *in vivo*, but the AS phenotype of the child, which implies a gain-of-function mechanism, does indicate that production of *FGFR2* containing the in-frame chimeric exon is likely to occur in critical target tissues; by contrast, skipping of both exons IIIb and IIIc would generate an isoform with loss-of-function properties [22].

The crystal structures of the *FGFR2* isoforms and their ligands reveal specific contacts between receptor loops present either in *FGFR2b* or in *FGFR2c*, and the distinct FGFs with which they interact [9,23]. The deletion in the patient causes several of these contacts to be lost. However, four of five key residues for FGF10 binding are retained, making it likely that *FGFR2b* properties persist in the chimeric exon (Figure 1D).

Conclusions

The case described here further demonstrates the specific mutational pathophysiology of AS, which results either from one of two missense substitutions in exon IIIa, or disruptions of exon IIIc splicing. The chimeric exon created by the deletion in this patient falls into the latter category. The encoded protein is predicted to retain *FGFR2b*-like binding properties, and hence lead

to autocrine activation of mesenchymal signalling mediated by FGF10 or a related ligand.

Consent

Written informed consent was obtained from the patient's parents for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Acknowledgements and Funding

We thank the family for their assistance with this work, and the Wellcome Trust for funding (078666 and 093329 to A.O.M.W.).

Author details

¹Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK. ²The Hospital for Sick Children, Toronto, Ontario, Canada.

Authors' contributions

SCB and REMK undertook clinical assessment; ALF performed laboratory experiments; ALF and AOMW wrote the paper. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 25 May 2011 Accepted: 23 September 2011

Published: 23 September 2011

References

1. Cohen MJ: **Apert Syndrome**. In *Craniosynostosis Diagnosis, Evaluation, and Management*. 2 edition. Edited by: Cohen MJ, MacLean R. Oxford: Oxford University Press; 2000:316-354.
2. Wilkie AO, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, Hockley AD, Hayward RD, David DJ, Pulleyn LJ, Rutland P, Malcolm S, Winter RM, Reardon W: **Apert syndrome results from localized mutations of *FGFR2* and is allelic with Crouzon syndrome**. *Nat Genet* 1995, **9**(2):165-172.
3. Wilkie AO: **Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations**. *Cytokine Growth Factor Rev* 2005, **16**(2):187-203.
4. Ornitz DM: **FGF signaling in the developing endochondral skeleton**. *Cytokine Growth Factor Rev* 2005, **16**(2):205-213.
5. Ibrahimi OA, Chiu ES, McCarthy JG, Mohammadi M: **Understanding the molecular basis of Apert syndrome**. *Plast Reconstr Surg* 2005, **115**(1):264-270.
6. Wilkie AO, Patey SJ, Kan SH, van den Ouweland AM, Hamel BC: **FGFs, their receptors, and human limb malformations: clinical and molecular correlations**. *Am J Med Genet* 2002, **112**(3):266-278.
7. Mohammadi M, Olsen SK, Ibrahimi OA: **Structural basis for fibroblast growth factor receptor activation**. *Cytokine Growth Factor Rev* 2005, **16**(2):107-137.
8. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM: **Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family**. *J Biol Chem* 2006, **281**(23):15694-15700.
9. Yeh BK, Igarashi M, Eliseenkova AV, Plotnikov AN, Sher I, Ron D, Aaronson SA, Mohammadi M: **Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors**. *Proc Natl Acad Sci USA* 2003, **100**(5):2266-2271.
10. Anderson J, Burns HD, Enriquez-Harris P, Wilkie AO, Heath JK: **Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand**. *Hum Mol Genet* 1998, **7**(9):1475-1483.
11. Ibrahimi OA, Eliseenkova AV, Plotnikov AN, Yu K, Ornitz DM, Mohammadi M: **Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome**. *Proc Natl Acad Sci USA* 2001, **98**(13):7182-7187.
12. Yu K, Herr AB, Waksman G, Ornitz DM: **Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome**. *Proc Natl Acad Sci USA* 2000, **97**(26):14536-14541.

13. Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh N, Linhardt RJ, Mohammadi M: **Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities.** *Hum Mol Genet* 2004, **13**(19):2313-2324.
14. Yu K, Ornitz DM: **Uncoupling fibroblast growth factor receptor 2 ligand binding specificity leads to Apert syndrome-like phenotypes.** *Proc Natl Acad Sci USA* 2001, **98**(7):3641-3643.
15. Bochukova EG, Roscioli T, Hedges DJ, Taylor IB, Johnson D, David DJ, Deiningner PL, Wilkie AO: **Rare mutations of FGFR2 causing apert syndrome: identification of the first partial gene deletion, and an Alu element insertion from a new subfamily.** *Hum Mutat* 2009, **30**(2):204-211.
16. Oldridge M, Zackai EH, McDonald-McGinn DM, Iseki S, Morriss-Kay GM, Twigg SR, Johnson D, Wall SA, Jiang W, Theda C, Jabs EW, Wilkie AO: **De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome.** *Am J Hum Genet* 1999, **64**(2):446-461.
17. Hajjhosseini MK, Duarte R, Pegrum J, Donjacour A, Lana-Elola E, Rice DP, Sharpe J, Dickson C: **Evidence that Fgf10 contributes to the skeletal and visceral defects of an Apert syndrome mouse model.** *Dev Dyn* 2009, **238**(2):376-385.
18. Hajjhosseini MK, Wilson S, De Moerlooze L, Dickson C: **A splicing switch and gain-of-function mutation in Fgfr2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes.** *Proc Natl Acad Sci USA* 2001, **98**(7):3855-3860.
19. Hovhannisyann RH, Carstens RP: **A novel intronic cis element, ISE/ISS-3, regulates rat fibroblast growth factor receptor 2 splicing through activation of an upstream exon and repression of a downstream exon containing a noncanonical branch point sequence.** *Mol Cell Biol* 2005, **25**(1):250-263.
20. Takeuchi A, Hosokawa M, Nojima T, Hagiwara M: **Splicing reporter mice revealed the evolutionally conserved switching mechanism of tissue-specific alternative exon selection.** *PLoS One* 2010, **5**(6):e10946.
21. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP: **ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing.** *Mol Cell* 2009, **33**(5):591-601.
22. Wheldon LM, Khodabukus N, Patey SJ, Smith TG, Heath JK, Hajjhosseini MK: **Identification and characterization of an inhibitory fibroblast growth factor receptor 2 (FGFR2) molecule, up-regulated in an Apert Syndrome mouse model.** *Biochem J* 2011, **436**(1):71-81.
23. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M: **Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.** *Cell* 2000, **101**(4):413-424.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2350/12/122/prepub>

doi:10.1186/1471-2350-12-122

Cite this article as: Fenwick et al.: A deletion of *FGFR2* creating a chimeric IIIb/IIIc exon in a child with Apert syndrome. *BMC Medical Genetics* 2011 **12**:122.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

